UroGen Pharma Ltd.
URGN
$19.48
-$0.30-1.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.56% | -17.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.56% | -17.55% | |||
| Cost of Revenue | 52.36% | -5.71% | |||
| Gross Profit | 15.29% | -18.87% | |||
| SG&A Expenses | 23.54% | 3.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.86% | 11.82% | |||
| Operating Income | -12.28% | -38.99% | |||
| Income Before Tax | -12.60% | -24.63% | |||
| Income Tax Expenses | 158.93% | -85.20% | |||
| Earnings from Continuing Operations | -13.91% | -16.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.91% | -16.88% | |||
| EBIT | -12.28% | -38.99% | |||
| EBITDA | -12.28% | -39.08% | |||
| EPS Basic | -13.15% | -15.91% | |||
| Normalized Basic EPS | -11.84% | -27.64% | |||
| EPS Diluted | -13.15% | -15.91% | |||
| Normalized Diluted EPS | -11.84% | -27.64% | |||
| Average Basic Shares Outstanding | 0.67% | 0.83% | |||
| Average Diluted Shares Outstanding | 0.67% | 0.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||